跳至主要内容
临床试验/NCT03336138
NCT03336138已完成不适用

Application of Telemedicine to the Management of Aggressive Lymphomas: a Regional Comparative Study

University Hospital, Toulouse18 个研究点 分布在 1 个国家目标入组 350 人开始时间: 2012年1月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
350
试验地点
18
主要终点
dose-relative intensity (RDI)

研究概览

简要总结

The purpose of this study is to evaluate the value of AMA in a comparative multicenter regional study as a reference for aggressive lymphoma. The primary endpoint will be RDI. This study consider that the AMA support should allow a significant improvement of the RDI compared to the control group and thus impact the duration without progression. The study covers 350 patients recruited from 10 regional centers.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient with a recent diffuse large B cell lymphoma (LBDGC), histologically proven, with treatment not started
  • a priori likely to be treated by rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone every 21 days (R-CHOP21) for 8 cycles or rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (R-ACVBP).
  • Index international prognosis (IPI) measurable (IPI-aa), adjusted for age. Any IPI-aa is eligible.
  • accepting the study

排除标准

  • Patient with another type of lymphoma (including transformed follicular forms)
  • Patient having already started his treatment.
  • Life expectancy <3 months.
  • Carcinologic history
  • Serum positive for HIV or hepatitis B virus (HBV).

研究组 & 干预措施

AMA group

Active Comparator

Patient with telephone follow-up modality called AMA (Assistance for ambulatory patients)

干预措施: AMA (Assistance for ambulatory patients) (Other)

Control group

No Intervention

Patient with standard follow-up with no specific assistance for ambulatory patients

结局指标

主要结局

dose-relative intensity (RDI)

时间窗: through study completion, an average of 2 years

reduction of RDI

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (18)

Loading locations...

相似试验